Patents by Inventor Michael A. Gimbrone, Jr.
Michael A. Gimbrone, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7163808Abstract: Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g.Type: GrantFiled: November 20, 2001Date of Patent: January 16, 2007Assignees: California Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Jr., Hai U. Wang
-
Patent number: 6759210Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: March 28, 1997Date of Patent: July 6, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6534641Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: March 28, 1997Date of Patent: March 18, 2003Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6492126Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: August 11, 1999Date of Patent: December 10, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6359194Abstract: The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-&bgr; signaling pathways. Such transgenic mice may be used for screening compounds that may potentially useful for treating or preventing cardiovascular disease.Type: GrantFiled: April 8, 1999Date of Patent: March 19, 2002Assignees: Millennium Pharmaceuticals, Inc., Brigham & Women's HospitalInventors: Katherine Galvin, Dean A. Falb, Michael J. Donovan, Dennis Huszar, Michael A. Gimbrone, Jr.
-
Patent number: 6225084Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: September 9, 1997Date of Patent: May 1, 2001Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6221628Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: September 8, 1997Date of Patent: April 24, 2001Assignees: Brigham & Women's Hospital, Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6124433Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: September 26, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6087477Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: July 11, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6054558Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: September 9, 1997Date of Patent: April 25, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Womens's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6020463Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: February 1, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6018025Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: January 25, 2000Assignees: Millenium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 5968770Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 5708147Abstract: The invention relates to novel endothelial cell-leukocyte adhesion molecules designated ATHERO-ELAM. ATHERO-ELAM molecules are expressed on cultured endothelial cells stimulated with bacterial LPS and selectively mediate the binding of monocytes to the endothelial cells. Monoclonal antibodies specific for ATHERO-ELAM bind to vascular endothelial cells involved in early atherosclerotic lesions, but not to vascular endothelial cells from uninvolved arterial tissue. ATHERO-ELAM and antibodies directed to ATHERO-ELAM may be used in identifying early atherosclerotic lesions and in treating and preventing atherosclerosis.Type: GrantFiled: June 16, 1994Date of Patent: January 13, 1998Assignee: Brigham & Women's HospitalInventors: Michael A. Gimbrone, Jr., Myron I. Cybulsky, Tucker Collins
-
Patent number: 5632991Abstract: A method is provided for selectively targeting a therapeutic agent to a site of activated endothelium by administering a pharmaceutical composition comprising a therapeutically effective amount of an E-selectin (formerly called ELAM-1) specific monoclonal antibody conjugated to a therapeutic agent. An immunoconjugate comprising an E-selectin specific monoclonal antibody and a therapeutic agent is also provided. A method is also provided for the treatment of a vascular smooth muscle cell proliferative disorder, vasculitis, inflammation, post-reperfusion injury, microbial infections, acute or chronic allograft rejection, and leukemia, as well as for the inhibition of metastatic spread of tumor cells, by administering a pharmaceutical composition comprising a therapeutically effective amount of an E-selectin antibody, or antibody fragment, either alone, or conjugated to a therapeutic agent.Type: GrantFiled: December 29, 1994Date of Patent: May 27, 1997Assignee: Brigham & Women's HospitalInventor: Michael A. Gimbrone, Jr.
-
Patent number: 5451399Abstract: A novel polypeptide [Ala IL-8].sub.77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.Type: GrantFiled: October 19, 1992Date of Patent: September 19, 1995Assignees: Brigham and Women's Hospital, Genentech, Inc.Inventors: Michael A. Gimbrone, Jr., Martin S. Obin, Joffre B. Baker, Caroline A. Hebert
-
Patent number: 5302384Abstract: The present invention relates to intercellular adhesion inhibitory factors produced by cytokine activated endothelial cells. These factors designated endothelial-derived IL-8 find use in the diagnosis and treatment of inflammation and in the protection of endothelial cells from neutrophil mediated damage.Type: GrantFiled: February 25, 1993Date of Patent: April 12, 1994Assignee: Brigham and Women's HospitalInventors: Michael A. Gimbrone, Jr., M. Elyse Wheeler